(ANGO) AngioDynamics - Overview
Stock: Atherectomy, Thrombectomy, Ablation, Catheters, Guidewires
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 53.8% |
| Relative Tail Risk | -16.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.09 |
| Alpha | -19.76 |
| Character TTM | |
|---|---|
| Beta | 1.007 |
| Beta Downside | 1.156 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.26% |
| CAGR/Max DD | -0.11 |
Description: ANGO AngioDynamics December 28, 2025
AngioDynamics (NASDAQ: ANGO) is a U.S.–based medical-technology firm that designs, manufactures, and markets a range of surgical, diagnostic, and interventional devices used primarily for peripheral vascular disease, oncology, and various minimally invasive procedures.
Its product suite includes the Auryon atherectomy system for plaque removal while sparing vessel endothelium, the AlphaVac mechanical thrombectomy platform that operates without perfusionist support, and a family of thrombolytic catheters for clot dissolution in dialysis grafts, arteries, veins, and surgical bypasses. The company also offers the AngioVac venous drainage cannula and extracorporeal circuit for up to six-hour circulatory support, the NanoKnife irreversible electroporation (IRE) ablation system as a non-thermal alternative for soft-tissue tumors, and peripheral-access tools such as angiographic catheters, guidewires, and micro-introducer kits. Additional offerings cover drainage catheters (abscess, nephrostomy, biliary), the VenaCure EVLT laser system for superficial venous disease, and the Solero microwave tissue-ablation platform.
From a financial standpoint, AngioDynamics reported FY 2023 revenue of roughly $200 million, representing a 12 % year-over-year increase driven largely by higher adoption of its atherectomy and thrombectomy devices. The firm’s operating margin hovered near 15 %, but profitability is sensitive to reimbursement policy shifts and the competitive pricing pressure from larger med-tech players. Industry-wide, the peripheral vascular device market is projected to grow at a CAGR of about 6 % through 2029, fueled by an aging U.S. population and rising prevalence of peripheral artery disease (estimated to affect >8 % of adults over 65). A key macro driver is the ongoing push toward minimally invasive, catheter-based therapies, which aligns with AngioDynamics’ product focus.
For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -27.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 6.70 > 1.0 |
| NWC/Revenue: 29.09% < 20% (prev 30.28%; Δ -1.20% < -1%) |
| CFO/TA -0.02 > 3% & CFO -5.60m > Net Income -27.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.4m) vs 12m ago 1.18% < -2% |
| Gross Margin: 53.72% > 18% (prev 0.53%; Δ 5319 % > 0.5%) |
| Asset Turnover: 109.5% > 50% (prev 98.27%; Δ 11.24% > 0%) |
| Interest Coverage Ratio: -258.2 > 6 (EBITDA TTM -3.38m / Interest Expense TTM 106.0k) |
Altman Z'' -8.88
| A: 0.33 (Total Current Assets 161.3m - Total Current Liabilities 72.0m) / Total Assets 269.7m |
| B: -1.66 (Retained Earnings -446.4m / Total Assets 269.7m) |
| C: -0.10 (EBIT TTM -27.4m / Avg Total Assets 280.6m) |
| D: -4.77 (Book Value of Equity -445.1m / Total Liabilities 93.3m) |
| Altman-Z'' Score: -8.88 = D |
Beneish M -3.10
| DSRI: 0.96 (Receivables 44.4m/43.2m, Revenue 307.3m/286.5m) |
| GMI: 0.98 (GM 53.72% / 52.71%) |
| AQI: 1.01 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 1.07 (Revenue 307.3m / 286.5m) |
| TATA: -0.08 (NI -27.7m - CFO -5.60m) / TA 269.7m) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of ANGO shares?
Over the past week, the price has changed by +2.40%, over one month by +8.22%, over three months by -13.11% and over the past year by -1.66%.
Is ANGO a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ANGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.3 | 81.2% |
| Analysts Target Price | 19.3 | 81.2% |
| ValueRay Target Price | 10.3 | -3.7% |
ANGO Fundamental Data Overview February 10, 2026
P/S = 1.4164
P/B = 2.4684
P/EG = 1.87
Revenue TTM = 307.3m USD
EBIT TTM = -27.4m USD
EBITDA TTM = -3.38m USD
Long Term Debt = 10.1m USD (estimated: total debt 11.8m - short term 1.71m)
Short Term Debt = 1.71m USD (from shortTermDebt, last quarter)
Debt = 11.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.6m USD (from netDebt column, last quarter)
Enterprise Value = 405.4m USD (435.3m + Debt 11.8m - CCE 41.6m)
Interest Coverage Ratio = -258.2 (Ebit TTM -27.4m / Interest Expense TTM 106.0k)
EV/FCF = -43.46x (Enterprise Value 405.4m / FCF TTM -9.33m)
FCF Yield = -2.30% (FCF TTM -9.33m / Enterprise Value 405.4m)
FCF Margin = -3.04% (FCF TTM -9.33m / Revenue TTM 307.3m)
Net Margin = -9.02% (Net Income TTM -27.7m / Revenue TTM 307.3m)
Gross Margin = 53.72% ((Revenue TTM 307.3m - Cost of Revenue TTM 142.2m) / Revenue TTM)
Gross Margin QoQ = 53.05% (prev 55.29%)
Tobins Q-Ratio = 1.50 (Enterprise Value 405.4m / Total Assets 269.7m)
Interest Expense / Debt = 0.87% (Interest Expense 102.0k / Debt 11.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -21.6m (EBIT -27.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.24 (Total Current Assets 161.3m / Total Current Liabilities 72.0m)
Debt / Equity = 0.07 (Debt 11.8m / totalStockholderEquity, last quarter 176.3m)
Debt / EBITDA = 12.32 (negative EBITDA) (Net Debt -41.6m / EBITDA -3.38m)
Debt / FCF = 4.46 (negative FCF - burning cash) (Net Debt -41.6m / FCF TTM -9.33m)
Total Stockholder Equity = 181.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.87% (Net Income -27.7m / Total Assets 269.7m)
RoE = -15.31% (Net Income TTM -27.7m / Total Stockholder Equity 181.0m)
RoCE = -14.32% (EBIT -27.4m / Capital Employed (Equity 181.0m + L.T.Debt 10.1m))
RoIC = -11.86% (negative operating profit) (NOPAT -21.6m / Invested Capital 182.3m)
WACC = 9.39% (E(435.3m)/V(447.0m) * Re(9.63%) + D(11.8m)/V(447.0m) * Rd(0.87%) * (1-Tc(0.21)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.46%
Fair Price DCF = unknown (Cash Flow -9.33m)
EPS Correlation: -24.43 | EPS CAGR: -4.39% | SUE: 1.73 | # QB: 1
Revenue Correlation: -44.30 | Revenue CAGR: 1.92% | SUE: 0.68 | # QB: 0
EPS current Year (2026-05-31): EPS=-0.29 | Chg30d=+0.040 | Revisions Net=-1 | Growth EPS=-93.3% | Growth Revenue=+7.0%
EPS next Year (2027-05-31): EPS=-0.11 | Chg30d=+0.017 | Revisions Net=-1 | Growth EPS=+62.1% | Growth Revenue=+4.9%